TY - JOUR
T1 - Celastrol-induced weight loss is driven by hypophagia and independent from UCP1
AU - Pfuhlmann, Katrin
AU - Schriever, Sonja C.
AU - Baumann, Peter
AU - Kabra, Dhiraj G.
AU - Harrison, Luke
AU - Mazibuko-Mbeje, Sithandiwe E.
AU - Contreras, Raian E.
AU - Kyriakou, Eleni
AU - Simonds, Stephanie E.
AU - Tiganis, Tony
AU - Cowley, Michael A.
AU - Woods, Stephen C.
AU - Jastroch, Martin
AU - Clemmensen, Christoffer
AU - De Angelis, Meri
AU - Schramm, Karl Werner
AU - Sattler, Michael
AU - Messias, Ana C.
AU - Tschöp, Matthias H.
AU - Pfluger, Paul T.
N1 - Publisher Copyright:
© 2018 by the American Diabetes Association.
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Celastrol, a plant-derived constituent of traditional Chinese medicine, has been proposed to offer significant potential as an antiobesity drug. However, the molecular mechanism for this activity is unknown. We show that the weight-lowering effects of celastrol are driven by decreased food consumption. Although young Lepob mice respond with a decrease in food intake and body weight, adult Lepdb and Lepob mice are unresponsive to celastrol, suggesting that functional leptin signaling in adult mice is required to elicit celastrol's catabolic actions. Protein tyrosine phosphatase 1 (PTP1B), a leptin negative-feedback regulator, has been previously reported to be one of celastrol's targets. However, we found that global PTP1B knockout (KO) and wild-type (WT) mice have comparable weight loss and hypophagia when treated with celastrol. Increased levels of uncoupling protein 1 (UCP1) in subcutaneous white and brown adipose tissue suggest celastrol-induced thermogenesis as a further mechanism. However, diet-induced obese UCP1 WT and KO mice have comparable weight loss upon celastrol treatment, and celastrol treatment has no effect on energy expenditure under ambient housing or thermoneutral conditions. Overall, our results suggest that celastrol-induced weight loss is hypophagia driven and age-dependently mediated by functional leptin signaling. Our data encourage reconsideration of therapeutic antiobesity strategies built on leptin sensitization.
AB - Celastrol, a plant-derived constituent of traditional Chinese medicine, has been proposed to offer significant potential as an antiobesity drug. However, the molecular mechanism for this activity is unknown. We show that the weight-lowering effects of celastrol are driven by decreased food consumption. Although young Lepob mice respond with a decrease in food intake and body weight, adult Lepdb and Lepob mice are unresponsive to celastrol, suggesting that functional leptin signaling in adult mice is required to elicit celastrol's catabolic actions. Protein tyrosine phosphatase 1 (PTP1B), a leptin negative-feedback regulator, has been previously reported to be one of celastrol's targets. However, we found that global PTP1B knockout (KO) and wild-type (WT) mice have comparable weight loss and hypophagia when treated with celastrol. Increased levels of uncoupling protein 1 (UCP1) in subcutaneous white and brown adipose tissue suggest celastrol-induced thermogenesis as a further mechanism. However, diet-induced obese UCP1 WT and KO mice have comparable weight loss upon celastrol treatment, and celastrol treatment has no effect on energy expenditure under ambient housing or thermoneutral conditions. Overall, our results suggest that celastrol-induced weight loss is hypophagia driven and age-dependently mediated by functional leptin signaling. Our data encourage reconsideration of therapeutic antiobesity strategies built on leptin sensitization.
UR - http://www.scopus.com/inward/record.url?scp=85054016358&partnerID=8YFLogxK
U2 - 10.2337/db18-0146
DO - 10.2337/db18-0146
M3 - Article
C2 - 30158241
AN - SCOPUS:85054016358
SN - 0012-1797
VL - 67
SP - 2456
EP - 2465
JO - Diabetes
JF - Diabetes
IS - 11
ER -